drugset / Trial / NCT06601465
COgnitioN With VERiciGuat Evaluation in Heart Failure
Phase 2
Recruiting
120 enrolled
University of Alberta
Heart and Stroke Foundation of Canada · collabOttawa Heart Institute Research Corporation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.
Timeline
- Start
- 2025-06-03
- Primary completion
- 2026-07
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vericiguat | Other / unclassified | 10 mg | Oral |